Phelan-McDermid syndrome data network: Integrating patient reported outcomes with clinical notes and curated genetic

Cartik Kothari1, Maxime Wack1, Claire Hassen-Khodja1

  • 1Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.

Insights

The Phelan-McDermid Syndrome Data Network (PMS_DN) integrates diverse patient data to advance research into this rare genetic disorder. This platform aids in understanding phenotype-genotype correlations and disease progression for improved patient outcomes.

Area of Science:

  • Neuroscience
  • Genetics
  • Bioinformatics

Background:

  • Heterogeneous patient data hinders neuropsychiatric disorder research, especially for rare conditions like Phelan-McDermid Syndrome (PMS).
  • Paucity of clinical data for rare disorders like PMS complicates understanding disease origins and progression.
  • Phelan-McDermid Syndrome is a rare genetic disorder associated with autism and intellectual disability.

Purpose of the Study:

  • To describe the Phelan-McDermid Syndrome Data Network (PMS_DN), a platform designed to facilitate research into PMS.
  • To integrate heterogeneous patient phenotype data (PROs, clinical notes) with genetic information for PMS research.
  • To provide authorized investigators with access to integrated PMS data and statistical tools for phenotype-genotype correlation and progression studies.

Main Methods:

  • Integrating patient-reported outcomes (PRO) and clinical notes with curated genetic data.
  • Developing a web portal (https://pmsdn.hms.harvard.edu) for authorized investigator access.
  • Utilizing distributed research networks like PCORnet PopMedNet for aggregate data sharing.

Main Results:

  • As of October 31, 2016, PMS_DN integrated data from 112 patients' clinical notes, 176 patients' genetic reports, and 415 patients' PRO data.
  • The platform facilitates research into phenotype-genotype correlation and disease progression in PMS.
  • PMS_DN is hosted on a scalable cloud environment, adhering to privacy regulations.

Conclusions:

  • The PMS_DN platform effectively integrates diverse patient data to overcome research challenges in rare disorders like PMS.
  • The initiative empowers patients and families in data management and research direction.
  • PMS_DN fosters collaborative research by providing access to integrated data and promoting data sharing through networks.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
51
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
41.0K